Praxis Precision Medicines (PRAX) FCF Margin (2023 - 2024)
Praxis Precision Medicines (PRAX) posted quarterly FCF Margin of 752.0% for Q4 2024, up 388120.0% year-over-year from N/an in Q1 2024, and up 91.74% quarter-over-quarter from 9105.96% in Q3 2024.
Praxis Precision Medicines (PRAX) FCF Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' FCF Margin history runs 2 years deep, the most recent figure standing at 752.0% for Q4 2024.
- In Q4 2024, FCF Margin rose 388120.0% year-over-year to 752.0%; the TTM figure through Sep 2025 stood at 3067.41% (up 313172.0% YoY), while the FY2024 annual figure was 1540.48%, up 300329.0% from the prior year.
- FCF Margin for Q4 2024 stood at 752.0%, up from 9105.96% in the prior quarter.
- The five-year high for FCF Margin was 752.0% in Q4 2024, with the low at 9105.96% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.72 Bn | 131.87 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.07 Bn | 77.08 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.59 Bn | 59.41 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.86 Bn | 36.77 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 22.62% |
| 7 | Royalty Pharma | 27.47 Bn | 26.64 Bn | - | 70.82% |
| 8 | BioNTech SE | 27.25 Bn | 8.85 Bn | 668.28 Mn | 41.07% |
| 9 | Insmed | 26.73 Bn | 25.57 Bn | 358.27 Mn | -22.35% |
| 10 | Praxis Precision Medicines | 10.71 Bn | 9.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -752.00% |
| Sep 30, 2024 | -9,105.96% |
| Jun 30, 2024 | -7,640.90% |
| Mar 31, 2024 | -4,839.21% |
| Dec 31, 2023 | -4,633.20% |
| Sep 30, 2023 | -4,971.15% |
| Jun 30, 2023 | -3,996.67% |
| Mar 31, 2023 | -4,809.08% |